What question did this study set out to answer?

To identify molecular biomarkers that impact the outcomes of elderly patients with mantle cell lymphoma enrolled in the V-RBAC trial.

July 26, 2026Blood AdvancesOpen Access

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial identifies molecular factors associated with outcomes in elderly mantle cell lymphoma, suggesting implications for risk assessment.

To identify molecular biomarkers that impact the outcomes of elderly patients with mantle cell lymphoma enrolled in the V-RBAC trial.
Phase II trial including 140 patients with molecular analysis of gene mutations and copy number variations.
Utilization of CAPP-Seq assay targeting 146 genes relevant to MCL pathogenesis.
Internal validation of a 4-factor molecular prognostic model using bootstrapping.
ATM mutations found in 55 patients (41.7%), with ATM deletion in 32 patients (24%).
Single-hit ATM alterations correlated with durable remission, independent of high-risk features.
Four distinct patient subgroups were identified based on a validated molecular prognostic model.

Moia et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial identifies molecular factors associated with outcomes in elderly mantle cell lymphoma, suggesting implications for risk assessment.